232 related articles for article (PubMed ID: 27007468)
1. Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments.
Ahmed SH; Moussa Sherif DE; Fouad Y; Kelany M; Abdel-Rahman O
Expert Opin Drug Saf; 2016 Jul; 15(7):911-23. PubMed ID: 27007468
[TBL] [Abstract][Full Text] [Related]
2. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
Bird BR; Swain SM
Clin Cancer Res; 2008 Jan; 14(1):14-24. PubMed ID: 18172247
[TBL] [Abstract][Full Text] [Related]
3. Cancer drug related cardiotoxicity during breast cancer treatment.
Giordano G; Spagnuolo A; Olivieri N; Corbo C; Campagna A; Spagnoletti I; Pennacchio RM; Campidoglio S; Pancione M; Palladino L; Villari B; Febbraro A
Expert Opin Drug Saf; 2016 Aug; 15(8):1063-74. PubMed ID: 27120499
[TBL] [Abstract][Full Text] [Related]
4. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors.
Schmitz KH; Prosnitz RG; Schwartz AL; Carver JR
Cancer; 2012 Apr; 118(8 Suppl):2270-6. PubMed ID: 22488701
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer treatment-induced cardiotoxicity.
Martel S; Maurer C; Lambertini M; Pondé N; De Azambuja E
Expert Opin Drug Saf; 2017 Sep; 16(9):1021-1038. PubMed ID: 28697311
[TBL] [Abstract][Full Text] [Related]
6. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
[TBL] [Abstract][Full Text] [Related]
7. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
Hollingsworth K; Romney MC; Crawford A; McAna J
J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Breast Radiotherapy and Cardiac Toxicity.
Yeboa DN; Evans SB
Semin Radiat Oncol; 2016 Jan; 26(1):71-8. PubMed ID: 26617212
[TBL] [Abstract][Full Text] [Related]
9. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
10. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
[TBL] [Abstract][Full Text] [Related]
11. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
12. Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer.
Meattini I; Guenzi M; Fozza A; Vidali C; Rovea P; Meacci F; Livi L
Breast Cancer; 2017 Jan; 24(1):52-62. PubMed ID: 27025498
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of Contemporary Breast Cancer Treatments.
Lee Chuy K; Yu AF
Curr Treat Options Oncol; 2019 May; 20(6):51. PubMed ID: 31073788
[TBL] [Abstract][Full Text] [Related]
14. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
[TBL] [Abstract][Full Text] [Related]
16. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?
Caron J; Nohria A
Curr Oncol Rep; 2018 Jun; 20(8):61. PubMed ID: 29876677
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
18. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer therapy-associated cardiovascular disease.
Zagar TM; Cardinale DM; Marks LB
Nat Rev Clin Oncol; 2016 Mar; 13(3):172-84. PubMed ID: 26598943
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]